Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601504
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-08
Brief Title:
Study of HMPL-760 Puls R-GemOx Versus Placebo Plus R-GemOx in RelapsedRefractory DLBCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase II Randomized Controlled Study to Evaluate the Efficacy Safety and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients with RelapsedRefractory Diffuse Large B-Cell LymphomaRR DLBCL
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with RelapsedRefractory Diffuse Large B-Cell Lymphoma RR DLBCL
Detailed Description:
A Phase II Randomized Controlled Study to Evaluate the Efficacy Safety and Pharmacokinetics of HMPL-760 in Combination with R-GemOx versus Placebo in Combination with R-GemOx in Patients with RelapsedRefractory Diffuse Large B-Cell Lymphoma RR DLBCL The study phases include screening period treatment period safety observation period PFS follow-up period and OS follow-up period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None